QPPV.COM KNOWLEDGE ASSESSMENT

Ferric Carboxymaltose: Hypophosphataemia, Osteomalacia and Post-Marketing Risk

Test your understanding of the concepts covered by Ferric Carboxymaltose: Hypophosphataemia, Osteomalacia and Post-Marketing Risk.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A report describes bone pain and a low phosphate result but contains no diagnostic work-up for osteomalacia. How should the case be represented?
Question 2 of 10 What is the most defensible interpretation of the PHOSPHARE-IDA trial proportions cited in the article?
Question 3 of 10 Which approach best supports reliable case identification when a report initially says only “iron infusion”?
Question 4 of 10 Under the 2026 US Injectafer label described in the article, which situation specifically calls for checking phosphate before a repeat course?
Question 5 of 10 A patient’s phosphate is normal before FCM, then falls over the following weeks. Which interpretation best fits the described mechanism?
Question 6 of 10 Which statement best distinguishes signal evaluation from assessment of risk-minimisation effectiveness?
Question 7 of 10 Which conclusion about spontaneous-report data is most appropriate when assessing the FCM safety signal?
Question 8 of 10 The EU Article 31 procedure includes several injectable iron formulations. What should an MAH avoid concluding from that scope alone?
Question 9 of 10 Which sequence best describes the proposed mechanism linking ferric carboxymaltose (FCM) to hypophosphataemia?
Question 10 of 10 A patient has inflammatory bowel disease, vitamin D deficiency and recent FCM exposure. Which causality interpretation best reflects the article?

Select an answer to continue.

QPPV.com